Rajesh P Ringe

Dr. Rajesh P Ringe

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2021 in ACS Infectious Diseases
Verified
Journal Article
Open access
SMSameer Kumar Malladi
Sameer Kumar Malladi
UPUnnatiben Rajeshbhai Patel
Unnatiben Rajeshbhai Patel
RRRaju S. Rajmani
Raju S. Rajmani
Randhir SinghRandhir Singh
Randhir Singh
SPSuman Pandey
Suman Pandey
RVRaghavan Varadarajan
Raghavan Varadarajan
The receptor binding domain (RBD) of SARS-CoV-2 is the primary target of neutralizing antibodies. We designed a trimeric, highly thermotolerant glycan engineered RBD by fusion to a heterologous, poorly immunogenic disulfide linked trimerization domain derived from cartilage matrix protein. The protein expressed at a yield of ∼80–100 mg/L in transiently transfected Expi293 cells, as well as CHO and HEK293 stable cell lines and formed homogeneous disulfide-linked trimers. When lyophilized, these possessed remarkable functional stability to transient thermal stress of up to 100 °C and were stable to long-term storage of over 4 weeks at 37 °C unlike an alternative RBD-trimer with a different trimerization domain. Two intramuscular immunizations with a human-compatible SWE adjuvanted formulation elicited antibodies with pseudoviral neutralizing titers in guinea pigs and mice that were 25–250 fold higher than corresponding values in human convalescent sera. Against the beta (B.1.351) variant of concern (VOC), pseudoviral neutralization titers for RBD trimer were ∼3-fold lower than against wildtype B.1 virus. RBD was also displayed on a designed ferritin-like Msdps2 nanoparticle. This showed decreased yield and immunogenicity relative to trimeric RBD. Replicative virus neutralization assays using mouse sera demonstrated that antibodies induced by the trimers neutralized all four VOC to date, namely B.1.1.7, B.1.351, P.1, and B.1.617.2 without significant differences. Trimeric RBD immunized hamsters were protected from viral challenge. The excellent immunogenicity, thermotolerance, and high yield of these immunogens suggest that they are a promising modality to combat COVID-19, including all SARS-CoV-2 VOC to date.

30 November 2023 in Journal of Virology
Verified
Journal Article
Closed access
SKSahil Kumar
Sahil Kumar
RDRathina Delipan
Rathina Delipan
DCDebajyoti Chakraborty
Debajyoti Chakraborty
KKKawkab Kanjo
Kawkab Kanjo
RSRandhir Singh
Randhir Singh
RRRajesh P Ringe
Rajesh P Ringe
SARS-CoV-2 has a remarkable ability to respond to and evolve against the selection pressure by host immunity exemplified by the emergence of Omicron lineage. Here, we characterized the functional significance of mutations in Omicron (BA.1 and BA.5) spike. By systematic transfer of mutations in wild type (WT) spike, we assessed neutralization sensitivity, fusogenicity, and TMPRSS2-dependence for entry. The data revealed that the mutations in both S1 and S2 complement to make Omicron a highly resistant variant. Strikingly, the mutations in Omicron S2 modulated the neutralization sensitivity to N-terminal domain and receptor binding domain antibodies, but not to S2-specific neutralizing antibodies, suggesting that the mutations in S2 were primarily acquired to gain resistance to S1-antibodies. Although all six mutations in S2 appeared to act in concert, D796Y showed the greatest impact on neutralization sensitivity and rendered the WT virus >100-fold resistant to S309, COVA2-17, and 4A8. The S2 mutations greatly reduced the antigenicity to neutralizing antibodies due to reduced exposure of epitopes. In addition to the effect on potency, S2 mutations increased antigenic heterogeneity of Omicron spike protein and neutralization of pseudoviruses plateaued below 100%. In terms of the entry pathway, S1 or S2 mutations only partially altered the entry phenotype of WT, and both sets of mutations were required for a complete switch to the endosomal route and loss of syncytia formation. In particular, N856K and L981F in Omicron BA.1 compromised fusion capacity which helps explain why subsequent Omicron variants lost them in order to regain fusogenicity. IMPORTANCE: The Omicron subvariants have substantially evaded host-neutralizing antibodies and adopted an endosomal route of entry. The virus has acquired several mutations in the receptor binding domain and N-terminal domain of S1 subunit, but remarkably, also incorporated mutations in S2 which are fixed in Omicron sub-lineage. Here, we found that the mutations in the S2 subunit affect the structural and biological properties such as neutralization escape, entry route, fusogenicity, and protease requirement. In vivo , these mutations may have significant roles in tropism and replication. A detailed understanding of the effects of S2 mutations on Spike function, immune evasion, and viral entry would inform the vaccine design, as well as therapeutic interventions aiming to block the essential proteases for virus entry. Thus, our study has identified the crucial role of S2 mutations in stabilizing the Omicron spike and modulating neutralization resistance to antibodies targeting the S1 subunit.

9 December 2021 in Frontiers in Immunology
Verified
Journal Article
Open access
SAShahbaz Ahmed
Shahbaz Ahmed
MKMohammad Suhail Khan
Mohammad Suhail Khan
SGSavitha Gayathri
Savitha Gayathri
Randhir SinghRandhir Singh
Randhir Singh
SKSahil Kumar
Sahil Kumar
RVRaghavan Varadarajan
Raghavan Varadarajan
Saturation suppressor mutagenesis was used to generate thermostable mutants of the SARS-CoV-2 spike receptor-binding domain (RBD). A triple mutant with an increase in thermal melting temperature of ~7°C with respect to the wild-type B.1 RBD and was expressed in high yield in both mammalian cells and the microbial host, Pichia pastoris, was downselected for immunogenicity studies. An additional derivative with three additional mutations from the B.1.351 (beta) isolate was also introduced into this background. Lyophilized proteins were resistant to high-temperature exposure and could be stored for over a month at 37°C. In mice and hamsters, squalene-in-water emulsion (SWE) adjuvanted formulations of the B.1-stabilized RBD were considerably more immunogenic than RBD lacking the stabilizing mutations and elicited antibodies that neutralized all four current variants of concern with similar neutralization titers. However, sera from mice immunized with the stabilized B.1.351 derivative showed significantly decreased neutralization titers exclusively against the B.1.617.2 (delta) VOC. A cocktail comprising stabilized B.1 and B.1.351 RBDs elicited antibodies with qualitatively improved neutralization titers and breadth relative to those immunized solely with either immunogen. Immunized hamsters were protected from high-dose viral challenge. Such vaccine formulations can be rapidly and cheaply produced, lack extraneous tags or additional components, and can be stored at room temperature. They are a useful modality to combat COVID-19, especially in remote and low-resource settings.

25 January 2023 in Viruses
Verified
Journal Article
Open access
PDF file
SKSara Khaleeq
Sara Khaleeq
NSNayanika Sengupta
Nayanika Sengupta
SKSahil Kumar
Sahil Kumar
UPUnnatiben Rajeshbhai Patel
Unnatiben Rajeshbhai Patel
RRRaju S. Rajmani
Raju S. Rajmani
RVRaghavan Varadarajan
Raghavan Varadarajan
Rapid emergence of the SARS-CoV-2 variants has dampened the protective efficacy of existing authorized vaccines. Nanoparticle platforms offer a means to improve vaccine immunogenicity by presenting multiple copies of desired antigens in a repetitive manner which closely mimics natural infection. We have applied nanoparticle display combined with the SpyTag–SpyCatcher system to design encapsulin–mRBD, a nanoparticle vaccine displaying 180 copies of the monomeric SARS-CoV-2 spike receptor-binding domain (RBD). Here we show that encapsulin–mRBD is strongly antigenic and thermotolerant for long durations. After two immunizations, squalene-in-water emulsion (SWE)-adjuvanted encapsulin–mRBD in mice induces potent and comparable neutralizing antibody titers of 105 against wild-type (B.1), alpha, beta, and delta variants of concern. Sera also neutralizes the recent Omicron with appreciable neutralization titers, and significant neutralization is observed even after a single immunization.

7 March 2023 in Pathogens
Verified
Journal Article
Open access
PDF file
HGHarry Garg
Harry Garg
RRRajesh P Ringe
Rajesh P Ringe
SDSupankar Das
Supankar Das
SPSuraj Parkash
Suraj Parkash
BTBhuwaneshwar Thakur
Bhuwaneshwar Thakur
AKAshwani Kumar
Ashwani Kumar
The World Health Organization (WHO) declared in May 2021 that SARS-CoV-2 is transmitted not only by close contact with infectious respiratory fluids from infected people or contaminated materials but also indirectly through air. Airborne transmission has serious implications for the control measures we can deploy, given the emergence of more transmissible variants. This emphasizes the need to deploy a mechanism to reduce the viral load in the air, especially in closed and crowded places such as hospitals, public transport buses, etc. In this study, we explored ultraviolet C (UVC) radiation for its ability to inactivate the SARS-CoV-2 particles present in aerosols and designed an air disinfection system to eliminate infectious viruses. We studied the virus inactivation kinetics to identify the UVC dosage required to achieve maximum virus inactivation. Based on the experimental data, UVC-based devices were designed for the sanitization of air through HVAC systems in closed spaces. Further, a risk assessment model to estimate the risk reduction was applied which showed that the use of UVC radiation could result in the reduction of the risk of infection in occupied spaces by up to 90%.

1 May 2023 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
NKNirmal Kumar
Nirmal Kumar
ITIrshad Maajid Taily
Irshad Maajid Taily
CSCharandeep Singh
Charandeep Singh
SKSahil Kumar
Sahil Kumar
RRRaju S. Rajmani
Raju S. Rajmani
IBIndranil Banerjee
Indranil Banerjee
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza A virus (IAV) poses enormous challenge in the development of broad-spectrum antivirals that are effective against the existing and emerging viral strains. Virus entry through endocytosis represents an attractive target for drug development, as inhibition of this early infection step should block downstream infection processes, and potentially inhibit viruses sharing the same entry route. In this study, we report the identification of 1,3-diphenylurea (DPU) derivatives (DPUDs) as a new class of endocytosis inhibitors, which broadly restricted entry and replication of several SARS-CoV-2 and IAV strains. Importantly, the DPUDs did not induce any significant cytotoxicity at concentrations effective against the viral infections. Examining the uptake of cargoes specific to different endocytic pathways, we found that DPUDs majorly affected clathrin-mediated endocytosis, which both SARS-CoV-2 and IAV utilize for cellular entry. In the DPUD-treated cells, although virus binding on the cell surface was unaffected, internalization of both the viruses was drastically reduced. Since compounds similar to the DPUDs were previously reported to transport anions including chloride (Cl-) across lipid membrane and since intracellular Cl-concentration plays a critical role in regulating vesicular trafficking, we hypothesized that the observed defect in endocytosis by the DPUDs could be due to altered Cl-gradient across the cell membrane. Usingin vitroassays we demonstrated that the DPUDs transported Cl-into the cell and led to intracellular Cl-accumulation, which possibly affected the endocytic machinery by perturbing intracellular Cl-homeostasis. Finally, we tested the DPUDs in mice challenged with IAV and mouse-adapted SARS-CoV-2 (MA 10). Treatment of the infected mice with the DPUDs led to remarkable body weight recovery, improved survival and significantly reduced lung viral load, highlighting their potential for development as broad-spectrum antivirals.